Is telomerase a viable target in cancer?

C. M. Buseman, W. E. Wright, J. W. Shay

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

The ideal cancer treatment would specifically target cancer cells yet have minimal or no adverse effects on normal somatic cells. Telomerase, the ribonucleoprotein reverse transcriptase that maintains the ends of human chromosome, is an attractive cancer therapeutic target for exactly this reason [1]. Telomerase is expressed in more than 85% of cancer cells, making it a nearly universal cancer marker, while the majority of normal somatic cells are telomerase negative. Telomerase activity confers limitless replicative potential to cancer cells, a hallmark of cancer which must be attained for the continued growth that characterizes almost all advanced neoplasms [2]. In this review we will summarize the role of telomeres and telomerase in cancer cells, and how properties of telomerase are being exploited to create targeted cancer therapies including telomerase inhibitors, telomerase-targeted immunotherapies and telomerase-driven virotherapies. A frank and balanced assessment of the current state of telomerase inhibitors with caveats and potential limitations will be included.

Original languageEnglish (US)
Pages (from-to)90-97
Number of pages8
JournalMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis
Volume730
Issue number1-2
DOIs
StatePublished - Feb 1 2012

Fingerprint

Telomerase
Neoplasms
Ribonucleoproteins
Telomere
Human Chromosomes
Immunotherapy
Therapeutics

Keywords

  • Immunotherapy
  • Senescence
  • Telomeres
  • Virotherapy

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Health, Toxicology and Mutagenesis

Cite this

Is telomerase a viable target in cancer? / Buseman, C. M.; Wright, W. E.; Shay, J. W.

In: Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, Vol. 730, No. 1-2, 01.02.2012, p. 90-97.

Research output: Contribution to journalArticle

@article{36e8d42d34cf4737894b16d48e9027b6,
title = "Is telomerase a viable target in cancer?",
abstract = "The ideal cancer treatment would specifically target cancer cells yet have minimal or no adverse effects on normal somatic cells. Telomerase, the ribonucleoprotein reverse transcriptase that maintains the ends of human chromosome, is an attractive cancer therapeutic target for exactly this reason [1]. Telomerase is expressed in more than 85{\%} of cancer cells, making it a nearly universal cancer marker, while the majority of normal somatic cells are telomerase negative. Telomerase activity confers limitless replicative potential to cancer cells, a hallmark of cancer which must be attained for the continued growth that characterizes almost all advanced neoplasms [2]. In this review we will summarize the role of telomeres and telomerase in cancer cells, and how properties of telomerase are being exploited to create targeted cancer therapies including telomerase inhibitors, telomerase-targeted immunotherapies and telomerase-driven virotherapies. A frank and balanced assessment of the current state of telomerase inhibitors with caveats and potential limitations will be included.",
keywords = "Immunotherapy, Senescence, Telomeres, Virotherapy",
author = "Buseman, {C. M.} and Wright, {W. E.} and Shay, {J. W.}",
year = "2012",
month = "2",
day = "1",
doi = "10.1016/j.mrfmmm.2011.07.006",
language = "English (US)",
volume = "730",
pages = "90--97",
journal = "Mutation Research",
issn = "0027-5107",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Is telomerase a viable target in cancer?

AU - Buseman, C. M.

AU - Wright, W. E.

AU - Shay, J. W.

PY - 2012/2/1

Y1 - 2012/2/1

N2 - The ideal cancer treatment would specifically target cancer cells yet have minimal or no adverse effects on normal somatic cells. Telomerase, the ribonucleoprotein reverse transcriptase that maintains the ends of human chromosome, is an attractive cancer therapeutic target for exactly this reason [1]. Telomerase is expressed in more than 85% of cancer cells, making it a nearly universal cancer marker, while the majority of normal somatic cells are telomerase negative. Telomerase activity confers limitless replicative potential to cancer cells, a hallmark of cancer which must be attained for the continued growth that characterizes almost all advanced neoplasms [2]. In this review we will summarize the role of telomeres and telomerase in cancer cells, and how properties of telomerase are being exploited to create targeted cancer therapies including telomerase inhibitors, telomerase-targeted immunotherapies and telomerase-driven virotherapies. A frank and balanced assessment of the current state of telomerase inhibitors with caveats and potential limitations will be included.

AB - The ideal cancer treatment would specifically target cancer cells yet have minimal or no adverse effects on normal somatic cells. Telomerase, the ribonucleoprotein reverse transcriptase that maintains the ends of human chromosome, is an attractive cancer therapeutic target for exactly this reason [1]. Telomerase is expressed in more than 85% of cancer cells, making it a nearly universal cancer marker, while the majority of normal somatic cells are telomerase negative. Telomerase activity confers limitless replicative potential to cancer cells, a hallmark of cancer which must be attained for the continued growth that characterizes almost all advanced neoplasms [2]. In this review we will summarize the role of telomeres and telomerase in cancer cells, and how properties of telomerase are being exploited to create targeted cancer therapies including telomerase inhibitors, telomerase-targeted immunotherapies and telomerase-driven virotherapies. A frank and balanced assessment of the current state of telomerase inhibitors with caveats and potential limitations will be included.

KW - Immunotherapy

KW - Senescence

KW - Telomeres

KW - Virotherapy

UR - http://www.scopus.com/inward/record.url?scp=84855500815&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855500815&partnerID=8YFLogxK

U2 - 10.1016/j.mrfmmm.2011.07.006

DO - 10.1016/j.mrfmmm.2011.07.006

M3 - Article

C2 - 21802433

AN - SCOPUS:84855500815

VL - 730

SP - 90

EP - 97

JO - Mutation Research

JF - Mutation Research

SN - 0027-5107

IS - 1-2

ER -